WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia.

ABSTRACT:

Background

The optimal strategy for vaccination to induce CD8⁺ T cell responses against WT1 is not known.

Methods

A pilot randomized study in HLA-A02⁺ patients to receive vaccination with WT1 in Montanide or in poly ICLC, a TLR3 agonist, to explore the novel immune adjuvant was conducted. Seven patients were randomized. Four patients received WT1 in Montanide, and three with WT1 in poly ICLC. Five patients were in morphologic remission and two had residual morphologic disease at the study entry.

Results

All patients finished the induction phase without any major toxicity except mild transient local injection reaction. One patient on the Montanide arm developed aseptic ulceration at two vaccine sites which healed without antibiotics. Three of 4 pa

SUBMITTER: Liu H 

PROVIDER: S-EPMC5765712 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature